KMTS

Kestra Medical Technologies, Ltd. (KMTS)

Market Closed
11 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
14. 91
-0.28
-1.84%
$
- Market Cap
- P/E Ratio
- Div Yield
310,400 Volume
- Eps
$ 15.19
Previous Close
Day Range
14.02 15.19
Year Range
14.02 26.15
Want to track KMTS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 1 days
Kestra Medical: Skipping A Heartbeat

Kestra Medical: Skipping A Heartbeat

Kestra Medical Technologies, Ltd. shows strong sales growth but faces significant operating losses and a concerning slowdown in sequential revenue growth. Despite a large addressable market and innovative cardiac device, the company's one-product focus and high valuation amplify risks. Recent quarters reveal only modest revenue increases, casting doubt on the sustainability of Kestra's growth trajectory post-IPO.

Seekingalpha | 1 month ago
Kestra Medical Technologies: A Potential Promising Public Offering

Kestra Medical Technologies: A Potential Promising Public Offering

Kestra Medical Technologies has seen rapid growth but incurs substantial operating losses, making its valuation exercise a hard one. The company's Cardiac Recovery System, including the ASSURE WCD, addresses a significant market need for sudden cardiac arrest intervention. Despite strong product adoption and a large addressable market, risks include high losses, being a one-product business, and potential growth slowdown.

Seekingalpha | 4 months ago
Kestra Medical Technologies aims to raise $150M in IPO

Kestra Medical Technologies aims to raise $150M in IPO

Kirkland, Wash.-based Kestra Medical Technologies is aiming to raise about $150 million in its initial public offering, pricing shares between $14 and $16 on the Nasdaq, according to a new regulatory filing.

Geekwire | 4 months ago
Kestra Medical Files For IPO On Substantial Operating Losses

Kestra Medical Files For IPO On Substantial Operating Losses

Kestra Medical Technologies, Ltd. is experiencing strong revenue growth but faces high operating losses and significant cash burn. The firm markets a wearable cardiac defibrillator, ASSURE WCD, with a lease business model, showing promising efficacy but dependent on reimbursement policies. The global cardiac arrest treatment market is projected to grow significantly, presenting opportunities for Kestra despite competition and regulatory risks.

Seekingalpha | 5 months ago